Core Viewpoint - The company has entered a strategic partnership with Silk Road Technology Co., Ltd. to promote the localization and market development of cognitive impairment digital therapy products in Malaysia and Southeast Asia, addressing the growing mental health needs in the region [1][4]. Group 1: Partnership Details - The collaboration includes the establishment of a specialized laboratory for cognitive impairment digital therapy in Malaysia, with Silk Road assisting in local approvals and logistics while the company provides technical and research support [3]. - Silk Road will lead the application for national innovation pilot projects, facilitating the company's engagement with Malaysian authorities [3]. - The partnership will also focus on clinical pilot projects in hospitals, with Silk Road identifying target hospitals and the company adapting products for local use [3]. - Both parties will work together to expand market presence in Malaysia and other Southeast Asian countries, including Indonesia, Thailand, and Vietnam [3]. Group 2: Market Context and Opportunities - Malaysia is facing challenges related to an aging population and increasing mental health demands, with 3.8 million people aged over 60 in 2023 and a significant shortage of mental health resources [1]. - The company is a pioneer in the cognitive impairment digital therapy market in China, with its core product being the first approved digital therapy for cognitive impairment, already included in the reimbursement catalog of 30 provinces in China [1]. - The partnership is expected to enhance the company's international presence and brand influence, leveraging Silk Road's extensive local resources and networks in Malaysia to accelerate market entry and improve commercial conversion efficiency [4].

本文源自：金融界AI电报 脑动极光-B(06681.HK)公告，公司与丝路之舟科技有限公司订立战略合作协议，双方将在马来西亚及东 南亚区域围绕认知障碍数字疗法产品的本土化落地、市场推广与科研转化等领域开展深度战略合作，共 同推动数字健康产业发展。根据协议，双方合作包括专项实验室建设：丝路之舟协助本公司在马来西亚 设立"认知障碍数字疗法专项实验室"，协调当地审批、场地规划及设备进口等事宜；本公司提供技术方 案与科研支持，主导研发与运营等。 ...

格隆汇2月5日丨脑动极光-B(06681.HK)宣布，公司与丝路之舟科技有限公司("丝路之舟")订立战略合作 协议，双方将在马来西亚及东南亚区域围绕认知障碍数字疗法产品的本土化落地、市场推广与科研转化 等领域开展深度战略合作，共同推动数字健康产业发展。 根据协议，双方合作主要包括以下内容： (V)东南亚市场开拓合作：以马来西亚合作为基础，逐步拓展至印尼、泰国、越南等其他东南亚国家。 协议为双方就马来西亚及东南亚市场合作订立的框架协议，後续具体执行细节将由双方进一步约定实施 细则。 董事会相信，此次合作将为公司带来长期发展机遇，为股东创造可持续价值，具体而言： (I)深化国际化布局，拓展海外市场：公司已先後在中国香港、澳门及新加坡开展业务推广及运营，积累 海外市场经验。本次与丝路之舟合作，标志着公司正式进入马来西亚市场，进一步拓展东南亚业务网 络，有助于将公司在中国市场验证的数字疗法经验与技术体系系统性地输出至具备成长潜力与政策支持 的区域市场，进一步扩大公司在国际上的品牌影响力与业务覆盖，提升全球影响力。 (II)借助本地资源，加速市场落地：丝路之舟在马来西亚拥有丰富的政府与医疗资源网络，可协助公司 高效完成 ...

Group 1 - The stock of Brainstorm Cell Therapeutics Inc. (脑动极光-B) experienced a significant increase, rising over 8% to a peak of 6.82 HKD per share on December 29, with a current price of 6.73 HKD per share at 14:41 [1][4] Group 2 - On December 29, Brainstorm Cell Therapeutics announced a strategic cooperation agreement with LaHespa Health Management Holdings Group (莱贺思宝), focusing on product promotion and market expansion in Singapore [4] - This partnership marks the official launch of the company's market layout and business development in Southeast Asia, leveraging its digital therapy experience and technology accumulated in the Chinese market [4] - The collaboration is expected to enhance the company's brand influence and accelerate product implementation in local medical institutions, thereby shortening the market introduction cycle and expanding into diverse markets in digital health management [4]

Core Viewpoint - The company, Brainstorm Cell Therapeutics (脑动极光-B), has seen its stock price increase by over 8% during trading, currently up by 5.87% at HKD 6.67, with a trading volume of HKD 110 million, following the announcement of a strategic partnership with Singapore's Lehe Health Management Group [1] Group 1: Strategic Partnership - The company has entered into a strategic cooperation agreement with Lehe Health Management Group to promote and expand its products in the Singapore market [1] - The collaboration will focus on the localization, system implementation, and personnel training support for cognitive impairment digital therapy products in Singapore [1] - Lehe Health Management Group will utilize its offline stores and member resources to target users for the company's products, providing comprehensive services including product introduction, trial guidance, purchase conversion, and after-sales support [1] Group 2: Market Expansion - Both companies will integrate their resources in products, channels, branding, and technology to jointly explore the Singapore market [1] - The partnership aims to facilitate the entry of the company's products into leading private and public hospitals in Singapore, enhancing the application and popularity of its products within the local healthcare system [1]

Core Viewpoint - The company Brainstorm Aurora-B (06681) has entered a strategic cooperation agreement with Singapore's Lehasiba Health Management Group to promote and expand its digital health products in the Singapore market [1] Group 1: Strategic Cooperation - The agreement focuses on product promotion and market expansion collaboration in Singapore [1] - Brainstorm Aurora will localize its cognitive impairment digital therapy products, support system implementation, and provide personnel training [1] - Lehasiba will utilize its offline stores and member resources to recommend the company's products to target users and manage the entire service process, including product introduction, trial guidance, purchase conversion, and after-sales support [1] Group 2: Market Expansion - Both companies will integrate resources such as products, channels, brands, and technology to jointly explore the Singapore market [1] - The collaboration aims to promote the company's products into leading private hospitals and public hospital systems in Singapore, enhancing the application and popularity of the products within the local healthcare system [1]

Group 1 - The company, Brainstorm Cell Therapeutics Inc. (06681.HK), has recently entered into a strategic cooperation agreement with Natural Health Solutions Programme Group Holdings to promote product marketing and market expansion in Singapore [1] - The collaboration aims to jointly advance the development of the digital health industry [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 BrainAurora Medical Technology Limited 腦動極光醫療科技有限公司 （於開曼群島註冊成立的有限公司） （股份代號：6681） 自願公告 訂立戰略合作協議以拓展新加坡市場及推動國際化佈局 本公告為腦動極光醫療科技有限公司（「本公司」，連同其附屬公司統稱「本集團」） 自願發佈的公告，目的是使廣大投資者瞭解本集團最新業務發展情況。 根據協議，雙方合作主要包括以下內容：(I)產品推廣合作：本公司負責認知障礙 數字療法產品在新加坡的本土化適配、系統落地及人員培訓支持；萊賀思寶將依 託其全部線下門店及會員資源，向目標用戶定向推薦本公司產品，並負責全流程 服務，包括產品介紹、試用引導、購買轉化及售後支持。(II)市場拓展協同：雙方 整合產品、渠道、品牌與技術等資源，共同開拓新加坡市場，重點推動本公司產 品進入新加坡頭部私立醫院及公立醫院體系，提升產品在當地醫療系統中的應用 與普及。 ...

Core Insights - The article highlights the successful IPO of Lighsong Health Group on the Hong Kong Stock Exchange, with a first-day stock price increase of 158.82% and a market capitalization of HKD 12.1 billion, marking a significant milestone for the company and the digital health industry in China [1] Group 1: Company Overview - Lighsong Health Group, established in 2014, has transformed from an insurance technology service provider to a comprehensive platform integrating health management, insurance technology, and medical services [1] - The company aims to enhance its "health management + insurance technology + medical services" ecosystem, focusing on AI technology upgrades and expanding into mental health and chronic disease management [1][6] Group 2: User Base and Engagement - As of June 2025, Lighsong Health's platform has accumulated 168.4 million registered users, with 60.4% aged between 20 and 45, representing a core health consumer demographic [2] - The platform boasts a high user retention rate of 92.2% after 13 months, significantly exceeding industry averages, indicating strong user engagement and loyalty [2] Group 3: AI Integration - Lighsong Health's competitive advantage lies in its deep integration of AI technology across its business operations, utilizing its self-developed AIcare technology stack for various applications including content creation, risk prediction, and health management [3] - The AI-driven marketing platform has generated 12.9 million business leads, with the value of leads from AI models increasing from 1.5% in 2022 to 23.3% in 2024 [3] Group 4: Financial Performance - The company's revenue is projected to reach CNY 945 million in 2024, reflecting a year-on-year growth of 92.9%, with further growth to CNY 656 million in the first half of 2025, marking an 84.7% increase [4] - The shift from an insurance-centric model to a health service-led approach has resulted in health service revenue rising from 15.2% in 2022 to 76.7% in the first half of 2025, with a compound annual growth rate of 221.26% [5] Group 5: Market Potential - The digital health industry in China is experiencing rapid growth, with the comprehensive health service and health insurance market expected to reach CNY 11.8 trillion by 2029, driven by increasing health awareness and supportive policies [5] - The "14th Five-Year Plan for National Health" and other government initiatives are set to accelerate digital health development, providing a favorable environment for companies like Lighsong Health [5] Group 6: Future Outlook - The IPO will provide Lighsong Health with the necessary capital to deepen technology research and expand its ecosystem, aiming to solidify its leading position in the industry [6] - The company is positioned to become a benchmark in China's digital health sector, leveraging its user base and technological advancements to deliver long-term value to investors [6]